Table of Contents
1. Overview and Scope
1.1. Research goal & scope
1.2. Research assumptions
1.3. Research methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-away
1.5. Stakeholders
2. Executive Summary
2.1. Market definition
2.2. Market segmentation
3. Blood cancer drugs market Insights
3.1. Blood Cancer Drug – Industry snapshot
3.1.1. Leading Companies
3.1.2. Emerging Companies & Technologies Platform
3.1.3. Key Companies to Watch
3.2. Blood Cancer Drug - Ecosystem analysis
3.2.1. Disease overview
3.2.2. Commercial Landscape
3.2.3. Future Treatment Paradigm
3.3. Blood cancer drugs market Dynamics
3.3.1. Blood Cancer Drug – Market Forces
3.3.1.1. Blood cancer drugs market Driver Analysis
3.3.1.2. Blood cancer drugs market Restraint/Challenges analysis
3.3.1.3. Blood Cancer Market Opportunity Analysis
3.3.2. Industry analysis - Porter's five forces
3.3.2.1. Bargaining power of supplier
3.3.2.2. Bargaining power of buyer
3.3.2.3. Threat of substitute
3.3.2.4. Threat of new entrant
3.3.2.5. Degree of competition
3.3.3. Blood cancer drugs market PEST Analysis, 2017
3.3.4. Blood cancer drugs market Value Chain Analysis
3.3.5. Blood Cancer Drug Industry Trends
3.3.6. Competitive Ranking Analysis
4. Blood cancer drugs market Size and Forecast, 2017-2025 by Blood Cancer Type
4.1. Key Findings
4.2. Lymphoma
4.2.1. Hodgkin Lymphoma
4.2.2. Non-Hodgkin Lymphoma
4.2.2.1. B-cell Lymphoma
4.2.2.1.1. Diffuse Large B-Cell Lymphoma
4.2.2.1.2. Mantle Cell Lymphoma
4.2.2.1.3. Burkitt Lymphoma
4.2.2.1.4. Central Nervous System Lymphoma
4.2.2.2. T-cell Lymphoma
4.2.2.2.1. Precursor T-Lymphoblastic Lymphoma
4.2.2.2.2. Peripheral T-Lymphoma
4.2.3. Leukemia
4.2.3.1. Acute Myeloid Leukemia
4.2.3.2. Chronic Myeloid Leukemia
4.2.3.3. Acute Lymphoblastic Leukemia
4.2.3.4. Chronic Lymphocytic Leukemia
4.2.4. Myeloma
4.2.4.1. Multiple Myeloma
5. Blood cancer drugs market Size and Forecast, 2017-2025 by Drugs
5.1. Rituaxan/Mabthera (Rituximab)
5.2. Gleevac/Glivec (Imatinib)
5.3. Revlimid (Lenalidomide)
5.4. Velcade (Bortezomib)
5.5. Tasigna (Nilotinib)
5.6. Pomalyst (Pomalidomide)
5.7. Vidaza (Azacitidine)
5.8. Kyprolis (Carfilzomib)
5.9. Adcetris (Brentuximab Vedotin)
5.10. Others
6. Blood cancer drugs market Size and Forecast, 2017-2025 by Treatment Approaches
6.1. Key Findings
6.2. Chemotherapeutic
6.3. mAbs/Targeted Therapies
6.4. Immunotherapeutic
7. Blood cancer drugs market Size and Forecast, 2017-2025 by Region
7.1. Key Findings
7.2. North America
7.2.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
7.2.2. Blood Cancer Drugs Market by drugs, 2017 – 2025
7.2.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
7.2.4. U.S.
7.2.4.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
7.2.4.2. Blood Cancer Drugs Market by drugs, 2017 – 2025
7.2.4.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
7.2.5. Canada
7.2.5.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
7.2.5.2. Blood Cancer Drugs Market by drugs, 2017 – 2025
7.2.5.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
7.3. Europe
7.3.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
7.3.2. Blood Cancer Drugs Market by drugs, 2017 – 2025
7.3.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
7.3.4. UK
7.3.4.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
7.3.4.2. Blood Cancer Drugs Market by drugs, 2017 – 2025
7.3.4.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
7.3.5. Germany
7.3.5.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
7.3.5.2. Blood Cancer Drugs Market by drugs, 2017 – 2025
7.3.5.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
7.3.6. France
7.3.6.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
7.3.6.2. Blood Cancer Drugs Market by drugs, 2017 – 2025
7.3.6.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
7.4. Asia-Pacific
7.4.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
7.4.2. Blood Cancer Drugs Market by drugs, 2017 – 2025
7.4.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
7.4.4. China
7.4.4.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
7.4.4.2. Blood Cancer Drugs Market by drugs, 2017 – 2025
7.4.4.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
7.4.5. Japan
7.4.5.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
7.4.5.2. Blood Cancer Drugs Market by drugs, 2017 – 2025
7.4.5.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
7.4.6. India
7.4.6.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
7.4.6.2. Blood Cancer Drugs Market by drugs, 2017 – 2025
7.4.6.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
7.5. Latin America
7.5.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
7.5.2. Blood Cancer Drugs Market by drugs, 2017 – 2025
7.5.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
7.5.4. Brazil
7.5.4.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
7.5.4.2. Blood Cancer Drugs Market by drugs, 2017 – 2025
7.5.4.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
7.5.5. Mexico
7.5.5.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
7.5.5.2. Blood Cancer Drugs Market by drugs, 2017 – 2025
7.5.5.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
7.6. Middle East & Africa
7.6.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
7.6.2. Blood Cancer Drugs Market by drugs, 2017 – 2025
7.6.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
8. Company Profiles
8.1. Johnson & Johnson Inc.
8.1.1. Overview
8.1.2. Financials
8.1.3. Product Benchmarking
8.1.4. Recent Developments
8.2. Amgen Inc.
8.2.1. Overview
8.2.2. Financials
8.2.3. Product Benchmarking
8.2.4. Recent Developments
8.3. Bayer AG.
8.3.1. Overview
8.3.2. Financials
8.3.3. Product Benchmarking
8.3.4. Recent Developments
8.4. Pfizer Inc.
8.4.1. Overview
8.4.2. Financials
8.4.3. Product Benchmarking
8.4.4. Recent Developments
8.5. Eli Lily & Co.
8.5.1. Overview
8.5.2. Financials
8.5.3. Product Benchmarking
8.5.4. Recent Developments
8.6. AstraZeneca
8.6.1. Overview
8.6.2. Financials
8.6.3. Product Benchmarking
8.6.4. Recent Developments
8.7. AbbVie Inc.
8.7.1. Overview
8.7.2. Financials
8.7.3. Product Benchmarking
8.7.4. Recent Developments
8.8. Roche Holding AG
8.8.1. Overview
8.8.2. Financials
8.8.3. Product Benchmarking
8.8.4. Recent Developments
8.9. Celgene Corporation.
8.9.1. Overview
8.9.2. Financials
8.9.3. Product Benchmarking
8.9.4. Recent Developments
8.10. Merck and Company
8.10.1. Overview
8.10.2. Financials
8.10.3. Product Benchmarking
8.10.4. Recent Developments
8.11. Novartis AG.
8.11.1. Overview
8.11.2. Financials
8.11.3. Product Benchmarking
8.11.4. Recent Developments
8.12. GlaxoSmithKline Pharmaceuticals Ltd.
8.12.1. Overview
8.12.2. Financials
8.12.3. Product Benchmarking
8.12.4. Recent Developments